Last reviewed · How we verify

Spinal Hydromorphone

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · FDA-approved active Small molecule

Spinal hydromorphone is an opioid analgesic that binds to opioid receptors in the spinal cord to block pain signal transmission.

Spinal hydromorphone is an opioid analgesic that binds to opioid receptors in the spinal cord to block pain signal transmission. Used for Chronic pain management via intrathecal delivery, Cancer pain, Post-operative pain.

At a glance

Generic nameSpinal Hydromorphone
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Drug classOpioid analgesic
TargetMu opioid receptor (primary), delta and kappa opioid receptors
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Hydromorphone is a semi-synthetic opioid agonist that acts on mu, delta, and kappa opioid receptors. When administered intrathecally (directly into the spinal fluid), it provides potent analgesia by inhibiting pain neurotransmission at the spinal level, allowing for lower systemic doses and reduced systemic side effects compared to oral or parenteral administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: